Insmed Incorporated (INSM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Insmed Incorporated (INSM) is down 43.3% since the beginning of the year. At $99 per share, INSM is trading 53.7% below its 52-week high of $213. Investors who bought $1,000 worth of INSM shares 5 years ago would now be looking at an investment worth $3,542.

Insmed Incorporated (INSM) has returned -43.34% so far this year and -3.97% over the past 12 months. Looking at the last ten years, INSM has achieved an annualized return of 26.23%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Jun 1, 2000, INSM's average daily return is +0.13%, while the average monthly return is +2.91%. At this rate, an investment would double in approximately 2.0 years.

Historically, 49% of months were positive and 51% were negative. The best month was Sep 2017 with a return of +151.3%, while the worst month was Sep 2002 at -77.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, INSM closed higher 47% of trading days. The best single day was Sep 5, 2017 with a return of +119.6%, while the worst single day was Sep 10, 2002 at -70.2%.

Insmed Incorporated has an annualized alpha of 29.87%, beta of 0.93, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since June 01, 2000.

• This stock participated in 149.23% of S&P 500 Index downside but only 124.36% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INSM ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Insmed Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Insmed Incorporated was 98.65%, occurring on Nov 25, 2011. Recovery took 3514 trading sessions.

The current Insmed Incorporated drawdown is 53.36%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Insmed Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Insmed Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.